Navigation Links
Personalized Stem Cells, Inc. Announces FDA Approval of IND Application for Treatment of Osteoarthritis with Stem Cells
Date:7/23/2019

Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell company, has received FDA approval for a New Drug (IND) application for use of a person’s own adipose-derived stem cells to treat their osteoarthritis. The first clinical trial, expected to begin in August, uses stem cells as a treatment of osteoarthritis in the knee.

This is the first of several planned clinical trials which will enable qualified PSC-enrolled physicians to provide FDA compliant, regulated quality cell therapy to patients suffering from osteoarthritis. PSC plans to conduct a series of FDA approved clinical trials starting with uses in orthopedics and expanding to other medical conditions in the future.

PSC is working with the FDA to provide alternatives to unregulated, in-clinic stem cell processing and unapproved “regenerative” therapies. The current environment of in-office, unregulated manufacturing of stem cells by physicians has come under serious regulatory action by the FDA, FTC, and the Federation of State Medical Boards. It is clear that the only allowed use of stem cells will be through legitimate FDA clinical trials with manufacturing in a controlled FDA inspected, GMP compliant facility.

PSC was founded by Robert Harman, DVM, MPVM and Michael Dale, both of whom also co-founded VetStem Biopharma and are both experienced serial entrepreneurs.

“This first clinical trial will not only provide an approved method for treatment of knee arthritis, but it will also demonstrate that it is possible to work within the FDA regulatory guidelines to bring advanced stem cell therapy to the public. We have made remarkable progress in obtaining our first approval in less than one year after forming the company,” says Mr. Dale.

PSC has enrolled a limited number of clinical sites around the U.S. to provide treatment of knee osteoarthritis using stem cells. The physicians in this first clinical trial are among the most experienced stem cell physicians in the country. Contact PSC for clinical trial information, clinical trial site locations, or investment information.

About Personalized Stem Cells, Inc.
Personalized Stem Cells was formed in 2018 to advance and legitimize human regenerative medicine. This privately held biopharmaceutical enterprise, based near San Diego (California), offers qualified physicians who enroll, an FDA compliant autologous stem cell product (from patient’s own fat tissue) for use in FDA approved clinical trials. PSC is driving development and adoption of stem cell and regenerative medicine within the FDA-IND process by providing quality manufactured, safety tested cells, and well-defined clinical trials. PSC has licensed a portfolio of over 70 issued patents in the field of regenerative medicine.

Read the full story at https://www.prweb.com/releases/personalized_stem_cells_inc_announces_fda_approval_of_ind_application_for_treatment_of_osteoarthritis_with_stem_cells/prweb16454322.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Personalized Medicine: A New Approach to Treat Periodontal Diseases
2. Zipongo Incorporates 23andMe Reports Into Personalized Nutrition Plans
3. Personalized Medicine - Scientific and Commercial Aspects - 318 Companies Profiled with 575 Collaborations - Research and Markets
4. NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology
5. @USANAincs Personalized Nutrition Program Wins Industry Innovation Award
6. "Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014
7. Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers
8. Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine
9. New partnership brings more personalized cancer treatment to Philadelphia
10. Patient-specific stem cells and personalized gene therapy
11. Genealogy and biogeography meet personalized medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2020)... ... August 06, 2020 , ... ... pleased to announce that Eric Chen and Jessica Wong have joined the company’s ... & Strategy, respectively. , Eric Chen heads development efforts for Alucio’s flagship product, ...
(Date:8/5/2020)... , ... August 05, 2020 , ... Regenative Labs has ... new innovations, CoreText™ and ProText™, making them the first Wharton’s jelly allografts to be ... a syringe. The company’s solutions are the first Wharton’s jelly allograft product to be ...
(Date:7/31/2020)... Md. (PRWEB) , ... July 30, 2020 , ... ... Innovation Research (SBIR) Phase II contract awarded by the Joint Science & Technology ... of this project is to develop, optimize, and scale-up a highly efficient mammalian ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 08, 2020 , ... Bode Technology, ... expansion of laboratory operations through its COVID-19 testing service, Bode-CARES . Bode-CARES ... , Bode-CARES provides a turnkey solution that includes a comprehensive collection ...
(Date:7/10/2020)... , ... July 09, 2020 , ... ... cell therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., as ... oversee the clinical development of Sentien’s lead product, SBI-101. Dr. Nissenson serves ...
(Date:7/1/2020)... ... June 29, 2020 , ... MedShift , ... in 2020, despite many obstacles created as a result of COVID-19. As a ... its partnered medical practices and medical manufacturers by expanding access to device offerings, ...
(Date:6/28/2020)... ... 2020 , ... The Indoor Lab, a leading provider of sensor solutions for ... types to ensure cleanliness, distancing and occupancy with its patent pending WipeAway™ technology using ... will provide a health performance index system that scores all aspects of compliance similar ...
Breaking Biology Technology: